Anthropometric data of subjects in two treatment strategies and three subgroups
| Strategy | Subgroup | ||||
| Reference | AHR | AHR# | S¶ | S+AHR+ | |
| Subjects n | 104 | 102 | 91 | 46 | 69 |
| Males/females n | 54/50 | 63/39 | 54/37 | 30/16 | 33/36 |
| Age yrs | 10.9±2.5 | 10.8±2.4 | 10.7±2.5 | 11.0±2.1 | 11.0±2.5 |
| Duration of asthma yrs | 7.1±3.0 | 7.3±3.1 | 7.3±3.0 | 7.0±3.3 | 7.3±3.0 |
| Duration of ICS usage yrs | 5.2±2.7 | 5.8±2.7 | 5.4±2.9 | 5.4±3.0 | 5.7±2.4 |
| Asthma exacerbations in year prior to study n | 12 | 25 | 20 | 5 | 12 |
| FEV1 % pred | 98±14 | 96±14 | 97±15 | 100±12 | 94±14 |
| FEV1/FVC % | 83±8 | 81±9 | 81±9 | 86±6 | 81±8 |
| PEF variability % | 7±4 | 7±4 | 6±3 | 7±5 | 8±5 |
| PD20 μg | 73 (0.8–>1570) | 68 (0.8–>1570) | 47 (3–148) | 553 (154–>1570) | 42 (0.8–144) |
| Run-in SS | 17 (0–87) | 17 (0–152) | 2 (0–13) | 28 (14–100) | 31 (15–152) |
Data are presented as mean±sd or median (range), unless otherwise stated. AHR: airway hyperresponsiveness; S: symptom; ICS: inhaled corticosteroid; FEV1: forced expiratory volume in one second; % pred: % predicted; FVC: forced vital capacity; PEF: peak expiratory flow; PD20: provocative dose of methacholine causing a 20% fall in FEV1; SS: cumulative symptom score during the last 14 days before the clinic visit. #: well-controlled symptoms and AHR during run-in; ¶: manifest symptoms without AHR during run-in; +: manifest symptoms and AHR during run-in.